NovaPharm Therapeutics (NPT) is an early stage biopharmaceutical company developing new therapeutic options in the treatment of undermanaged, underserved and unmet medical conditions.
We utilizes a lean development model that enables agility and flexibility at all stages of development. The NovaPharm model establishes early proof-of-concept (POC), reduces key risk factors and adds value to early/mid stage therapies.
NovaPharm initiated development of NPT101, a novel treatment for Complex Regional Pain Syndrome (CRPS) a devastating condition for which there are no approved treatments. We have recently partnered this compound with a leading pharmaceutical company.
We are actively expanding our development pipeline with a relentless focus on conditions and diseases for which patients have limited options. We are committed to expanding our model and product pipeline to successfully develop new high value therapeutic treatments.